FTC

Abbvie-Allergan complete, but critics continue to raise anti-competitive concerns
Abbvie-Allergan complete, but critics continue to raise anti-competitive concerns
Endpoints
AbbVie
Allergan
M&A
FTC
Flag link:
AbbVie, Allergan score FTC approval for $63B merger with one final hurdle left to go
AbbVie, Allergan score FTC approval for $63B merger with one final hurdle left to go
Fierce Pharma
AbbVie
Allergan
M&A
FTC
Flag link:
AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger
AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger
BioSpace
AbbVie
Allergan
FTC
M&A
Flag link:
AbbVie, Allergan merger may face regulatory delay due to COVID-19: report
AbbVie, Allergan merger may face regulatory delay due to COVID-19: report
Fierce Pharma
AbbVie
Allergan
FTC
M&A
COVID-19
Flag link:
The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers
The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers
Motley Fool
FDA
FTC
drug pricing
anti-competitive scheme
biosimilars
Flag link:
Martin Shkreli is sued by the FTC and NY attorney general for illegally cornering a market
Martin Shkreli is sued by the FTC and NY attorney general for illegally cornering a market
Stat
Martin Shkreli
FTC
New York
Vyera Pharmaceuticals
Daraprim
Flag link:
Roche's $4.8B deal for Spark cleared by FTC after long delay
Roche's $4.8B deal for Spark cleared by FTC after long delay
Biopharma Dive
Roche
Spark Therapeutics
M&A
FTC
Flag link:
82 Professors Call on Court to Support FTC Decision in Pay-for-Delay Case
82 Professors Call on Court to Support FTC Decision in Pay-for-Delay Case
RAPS.org
FTC
pay-for-delay
Endo Pharmaceuticals
generics
Flag link:
After big M&A year, will pharma move away from massive deals in 2020?
After big M&A year, will pharma move away from massive deals in 2020?
Fierce Pharma
M&A
Sanofi
Merck
AbbVie
Allergan
Bristol-Myers Squibb
Celgene
FTC
Flag link:
Disruptor of the Year: The Federal Trade Commission
Disruptor of the Year: The Federal Trade Commission
Biopharma Dive
FTC
M&A
Roche
Spark Therapeutics
Flag link:
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
Investors Business Daily
Bristol-Myers Squibb
Celgene
FTC
M&A
Flag link:
FTC requests AbbVie, Allergan for more information on $63 billion deal
FTC requests AbbVie, Allergan for more information on $63 billion deal
Reuters
FTC
M&A
AbbVie
Allergan
Flag link:
U.S. Senators urge FTC to scrutinize multi-billion dollar pharma mergers
U.S. Senators urge FTC to scrutinize multi-billion dollar pharma mergers
Reuters
Senate
FTC
M&A
Flag link:
[podcast+transcript]Why Amgen's Spending Billions to Buy This 1 Drug
[podcast+transcript]Why Amgen's Spending Billions to Buy This 1 Drug
Motley Fool
FTC
Amgen
Celgene
Bristol-Myers Squibb
M&A
Otezla
Flag link:
Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?
Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?
Endpoints
Roche
Spark Therapeutics
FTC
CMA
M&A
Flag link:
Six burning Otezla questions
Six burning Otezla questions
EP Vantage
Celgene
Otezla
Amgen
drug pricing
FTC
Tyk2
Bristol-Myers Squibb
Flag link:
FTC investigates J&J contracts regarding the drugmaker's blockbuster Remicade
FTC investigates J&J contracts regarding the drugmaker's blockbuster Remicade
Endpoints
FTC
JNJ
Remicade
antitrust
biosimilars
Pfizer
Inflectra
Flag link:
Reckitt Benckiser Group PLC agrees to pay $1.4 billion to settle whistleblower cases
Reckitt Benckiser Group PLC agrees to pay $1.4 billion to settle whistleblower cases
CP Wire
whistleblower lawsuits
Reckitt Benckiser
FTC
opioids
opioid addiction
Suboxone
Flag link:
Reckitt Benckiser Group PLC agrees to pay $1.4 billion to settle whistleblower cases
whistleblower lawsuits
Reckitt Benckiser
FTC
opioids
opioid addiction
Suboxone
Flag link:
In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
Endpoints
Bristol-Myers Squibb
Opdivo
Otezla
M&A
FTC
Celgene
Flag link:

Pages